50 results about "Lysyl oxidase" patented technology

Disclosed are methods of identifying lysyl oxidase inhibitors and the use of such inhibitors to prevent and treat tumors, particularly metastatic tumors, alone and in combination with chemotherapeutic agents. Further disclosed is the use of lysyl oxidase levels for measuring metastatic potential and survival.

The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of lysyl oxidase (LOX) or a lysyl oxidase-like protease (LOXL).

Disclosed herein are methods and compositions for enhancing the cell-killing activity of anti-neoplastic agents by inhibiting the activity of a lysyl oxidase-type enzyme. Also disclosed are methods for screening for chemotherapeutic agents, and for molecules that enhance the activity of chemotherapeutic agents, using cells grown on an extracellular matrix.

Methods of making collagen with hosts, and vectors that express collagen, and collagen post-translation enzymes are disclosed. Collagen post-translation enzymes include prolyl-4-hydroxylase, lysyl hydroxylase, lysyl oxidase, C-proteinase, and N-proteinase, and these enzymes increase the yield of properly folded, recombinant collagen in non-mammalian hosts. The collagens produced by these methods, hosts, and vectors include both homotrimer and heterotrimer collagen made from single or multiple collagen genes, respectively.

The invention discloses a novel human-like collagen haemostatic dressing which has good biocompatibility, can be absorbed and is rich in calcium, zinc, copper and iron, and discloses a preparation method of the novel human-like collagen haemostatic dressing. The preparation method comprises the following steps: by taking modified protein obtained by chelating humanized human-like collagen prepared by high-density fermentation with calcium, zinc, copper and iron ions respectively as a raw material as well as taking lysyloxidase existing in mammals as a cross-linking agent, carrying out low-temperature cross-linking reaction and freeze-drying processes to obtain the novel collagen haemostatic dressing which can be used for hemostasis of wounds and postoperative hemostasis. The preparation method disclosed by the invention has the advantages that the raw materials are easy to obtain, the cost is low, the synthetic process is simple and easy to realize, process amplification is easy, and the reproducibility is good; and the human-like collagen haemostatic dressing prepared by the preparation method does not have animal-derived virus hidden danger, has an obvious haemostatic effect, can be used for hemostasis of various wounds and postoperative hemostasis, and can be used for basic research and application of related fields, such as biomedical tissue engineering.

The invention discloses novel antibacterial human-like collagen wound care film dressing which has good biocompatibility, is absorbable and is enriched with calcium, zinc, copper and silver elements as well as a preparation method of the film dressing. According to the preparation method, modified protein obtained by chelating calcium, zinc and copper ions on human-derived human-like collagen prepared through high-density fermentation is taken as a raw material, lysyl oxidase in a mammal body is taken as a cross-linking agent, and the novel antibacterial human-like collagen wound care film dressing which can be used for burn scald and skin wound is obtained through supporting of free silver ions due to the high absorption characteristic in the low-temperature crosslinking reaction and freeze drying process. Hidden danger caused by animal-derived viruses is avoided, and the hemostatic effect is remarkable; the contained silver ions can prevent the wound from being invaded by bacteria. The care dressing can be used for treating various wounds and has a wide application prospect.

Methods are provided for assessing the risk of developing restenosis in an individual, by detecting the presence of biologically important polymorphisms in genes involved in the formation of the elastin fiber network. In particular, detection of polymorphorphisms in the elastin, fibrillin, fibrillin-1, fibrillin-2, lysyl oxidase, microfibril-associated glycoprotein, biglycan, osteopontin, and/or decorin genes allows the rapid and objective prediction of the risk of developing restenosis. Methods for treating restenosis and for reducing its recurrence also are provided.

The invention discloses a kit for detecting a susceptibility gene of glaucoma. The kit comprises specific primer pairs, specific fluorescent probe pairs, conventional components and the like, wherein the specific primer pairs and the specific fluorescent probe pairs are used for simultaneously detecting a No.rs3825942 SNP (single nucleotide polymorphism) site on an LOXL (lysyl oxidase-like)1 gene and a No.rs4236601 SNP site on a CAV (chicken anemia virus)1/CAV2 gene; the conventional components are used for fluorescent quantitative PCR (polymerase chain reaction) detection. The kit is used for evaluating the risk of suffering from glaucoma by individuals by simultaneously detecting SNP site genotypes of LOXL1 and CAV1/CAV2 closely related to glaucoma.

The present disclosure relates to a method of maintaining luminal patency of a blood vessel following vessel injury, the method including administering a composition comprising at least one lysyl oxidase inhibitor and D-penicillamine to a subject in need thereof Compositions to support the methods are also provided.

Lysyl oxidase derived from filamentous fungi and a DNA encoding thereof are provided. Lysyl oxidase including a protein described in of the following (a) or (b): (a) a protein having an amino acid sequence set forth in SEQ ID NO: 2; or (b) a protein having an amino acid sequence obtained by modifying a part of the amino acid sequence set forth in SEQ ID NO: 2, and functioning as lysyl oxidase.

An article of manufacture is disclosed which comprises at least two active agents, wherein a first of the two active agents comprises an anti-cancer agent or an antifibrotic agent and a second of the at least two active agents downregulates the activity and/or expression of lysyl-oxidase like protein-2 (LOXL-2) and which is capable of altering the structure of the extracellular matrix.

The invention discloses a compound lozenge controlling childe tooth decay, and belongs to the technical field of medicines. The lozenge comprises medicinal compositions and auxiliary material compositions. The medicinal compositions comprise, in parts by weight, 1-3 parts of lysyl oxidase, 1.5-2.5 parts of D-galactose, 5-8 parts of nanometer diatomite, 0.2-0.6 part of calcium dihydrogen phosphate, 0.11-0.13 part of chromium picolinate, 0.08-0.1 part of tretinoin, 0.02-0.03 part of tiamcinolone acetonide. The auxiliary material compositions comprise, in parts by weight, 70-100 parts of a medicine carrier, 0.12-0.25 part of a solvent, 0.01-0.03 part of an aseptic, 0.14-0.26 part of compound vitamin, and 2-5 parts of a corrigent. The lozenge contains multiple effective compositions, is reasonable in matching ratio, is capable of resisting bacteria, diminishing inflammation, removing dental plaque and harmful bacteria, preventing and treating decayed teeth and preventing carious teeth, does not cause anaphylactic reaction, and enhances oral cavity health-care effect.

The present invention relates generally to methods of use and compositions useful for treating skin. The composition includes a combination of Phoenix dactylifera extract, tea tree oil, Myrothamnus flabellifolia extract, and saccharide isomerate. This combination can be used to create topical skin compositions that reduce rosacea, erythema, and/or inflammation, and inhibit nitric oxide synthase, increase α2A adrenergic receptor agonist activity, reduce oxidation, increase anti-oxidant capacity of a composition or of skin, inhibit cyclooxygenase-2 (COX-2) production, inhibit vascular endothelial growth factor (VEGF) production, inhibit interleukin-6 (IL-6) and interleukin-8 (IL-8) production, reduce tumor necrosis factor alpha (TNF-α) production, increase collagen stimulation, increase lysyl oxidase expression, inhibit matrix metalloproteinase 1 (MMP1) activity, increase occludin production, increase filaggrin production, and increase skin moisturization. This combination can also be used to reduce transient or persistent erythema, telangiectasia, inflammatory papules and/or pustules, transient or persistent flushing of the skin, and/or hyperplasia of a connective tissue.

A method for assessing the tenderness of meat from an animal, comprising the step of testing the animal for the presence or absence of a genetic marker selected from the group consisting of:

• • (1) an allele of the gene encoding calpastatin (CAST) associated with peak-force variation or genetic variation located other than in the CAST gene which shows allelic association with the CAST allele; and
  • (2) an allele of the gene encoding lysyl oxidase (LOX) associated with instron compression of the semitendinosis muscle or genetic variation located other than in the LOX gene which shows allelic association with the LOX allele.

The disclosure relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, Formula (I) as defined herein. Compounds according to Formula I are pharmacologically effective as lysyl oxidase (LOX) inhibitors and are believed to be useful in the treatment of, for instance, cancer.

The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.

Methods are disclosed for treating a subject with a disorder, such as, but not limited to, a) fibrosis of an organ or tissue; b) solid organ transplant rejection; or c) a cardiac disease that is not myocardial infarction or myocardial ischemia. These methods include selecting a subject having or at risk of having the disorder, and administering to the subject a therapeutically effective amount of isolated nanovesicles derived from an extracellular matrix, wherein the nanovesicles contain interleukin (IL)-33 and comprise lysyl oxidase, and wherein the nanovesicles a) do not express CD63 or CD81, or b) are CD63loCD81lo. In additional embodiments, methods are disclosed for increasing myoblast differentiation.

A skin line restoration cream includes, by weight, 20 parts of saffron crocus, 45 parts of angelica sinensis, 45 parts of radix salviae miltiorrhizae, 30 parts of paeonia veitchii, 25 parts of rhizomachuanxiong, and 30 parts of walnut kernels. Through exogenous stimulation and technology of inducing conversion of phenotype of smooth muscle, the skin line restoration cream, which is made from purenatural traditional Chinese medicine extracts and lysyloxidase, can permeate to deeply inside skin and stimulate activity of static fibrocytes, thus regenerating elastic fibers and enabling skin to be restored into smooth, elastic and glossy status. Through effective combination of the traditional Chinese medicine extracts and skincare products, a problem of discomfort on skin during storage andapplication of the traditional Chinese medicines is solved effectively. The skin line restoration cream is convenient to use and can work just by smearing the cream on skin without external application. The cream not only solves the problem of skin line restoration and also can moisturize skin.